Regeneron director Christine Poon sells 7,830 shares

The six reported sales had volume-weighted average prices between $966.74 and $971.31 per share.

Available on EDGAR 11/04/2026 - 04:10 PM EST Accepted by SEC EDGAR 11/04/2026 - 04:09 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Regeneron Pharmaceuticals, Inc. director Christine A. Poon exercised a non-qualified stock option for 7,830 common shares on November 2, 2026, at $376.69 per share, then sold 7,830 shares in six transactions that day. The reported volume-weighted average prices ranged from $966.74 to $971.31 per share. The option's expiration date was January 3, 2027.

Insider Trade Summary

Exercise and Sale: 7,830 shares ($4.64M approx. pre-tax spread)

Exercise and Sale 8 txns

Insider POON CHRISTINE A

Role Director

Sold 7,830 shs ($7.59M)

Approx. gross sale proceeds $7.59M

Approx. exercise cost $2.95M

Approx. pre-tax spread $4.64M

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy) F7	7,830	$0.00	$0.00
Exercise	Common Stock	7,830	$376.69	$2.95M
Sale	Common Stock F1	218	$966.74	$211K
Sale	Common Stock F2	772	$967.38	$747K
Sale	Common Stock F3	2,499	$968.58	$2.42M
Sale	Common Stock F4	3,203	$969.50	$3.11M
Sale	Common Stock F5	937	$970.51	$909K
Sale	Common Stock F6	201	$971.31	$195K

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 5,219 shares (Direct)

Footnotes (7)

1. F1. Represents volume-weighted average price of sales of 218 shares of Company stock on November 2, 2026 at prices ranging from $966.39 to $966.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
2. F2. Represents volume-weighted average price of sales of 772 shares of Company stock on November 2, 2026 at prices ranging from $967.06 to $967.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
3. F3. Represents volume-weighted average price of sales of 2,499 shares of Company stock on November 2, 2026 at prices ranging from $968.00 to $968.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
4. F4. Represents volume-weighted average price of sales of 3,203 shares of Company stock on November 2, 2026 at prices ranging from $969.01 to $969.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
5. F5. Represents volume-weighted average price of sales of 937 shares of Company stock on November 2, 2026 at prices ranging from $970.00 to $970.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
6. F6. Represents volume-weighted average price of sales of 201 shares of Company stock on November 2, 2026 at prices ranging from $971.16 to $971.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
7. F7. The stock option vested in three equal annual installments, commencing one year after the date of grant.

Key Figures

Non-qualified stock options exercised: 7,830 options Exercise price: $376.69 per share Sale volume-weighted average price: $966.74 per share +5 more

8 metrics

Non-qualified stock options exercised 7,830 options November 2, 2026

Exercise price $376.69 per share Option exercised November 2, 2026

Sale volume-weighted average price $966.74 per share 218 shares sold November 2, 2026

Sale volume-weighted average price $967.38 per share 772 shares sold November 2, 2026

Sale volume-weighted average price $968.58 per share 2,499 shares sold November 2, 2026

Sale volume-weighted average price $969.50 per share 3,203 shares sold November 2, 2026

Sale volume-weighted average price $970.51 per share 937 shares sold November 2, 2026

Sale volume-weighted average price $971.31 per share 201 shares sold November 2, 2026

Key Terms

Non-Qualified Stock Option (right to buy), volume-weighted average price, vested

3 terms

Non-Qualified Stock Option (right to buy) financial

"Non-Qualified Stock Option (right to buy)"

volume-weighted average price financial

"Represents volume-weighted average price of sales"

Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.

vested financial

"The stock option vested in three equal annual installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many REGN shares did director Christine A. Poon sell?

Christine A. Poon sold 7,830 Regeneron common shares on November 2, 2026, across six reported transactions, with volume-weighted average prices ranging from $966.74 to $971.31 per share. No Rule 10b5-1 plan is reported for the transactions.

What were the terms of Christine A. Poon's REGN stock-option exercise?

Poon exercised a non-qualified stock option for 7,830 common shares at $376.69 per share on November 2, 2026. The option's stated expiration date was January 3, 2027, and it vested in three equal annual installments beginning one year after its grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POON CHRISTINE A

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NEW YORK 10591

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		M		7,830	A	$376.69	13,049	D
Common Stock	11/02/2026		S		218	D	$966.74(1)	12,831	D
Common Stock	11/02/2026		S		772	D	$967.38(2)	12,059	D
Common Stock	11/02/2026		S		2,499	D	$968.58(3)	9,560	D
Common Stock	11/02/2026		S		3,203	D	$969.5(4)	6,357	D
Common Stock	11/02/2026		S		937	D	$970.51(5)	5,420	D
Common Stock	11/02/2026		S		201	D	$971.31(6)	5,219	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$376.69	11/02/2026		M			7,830	(7)	01/03/2027	Common Stock	7,830	$0.0	0	D

Explanation of Responses:

1. Represents volume-weighted average price of sales of 218 shares of Company stock on November 2, 2026 at prices ranging from $966.39 to $966.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

2. Represents volume-weighted average price of sales of 772 shares of Company stock on November 2, 2026 at prices ranging from $967.06 to $967.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

3. Represents volume-weighted average price of sales of 2,499 shares of Company stock on November 2, 2026 at prices ranging from $968.00 to $968.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

4. Represents volume-weighted average price of sales of 3,203 shares of Company stock on November 2, 2026 at prices ranging from $969.01 to $969.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

5. Represents volume-weighted average price of sales of 937 shares of Company stock on November 2, 2026 at prices ranging from $970.00 to $970.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

6. Represents volume-weighted average price of sales of 201 shares of Company stock on November 2, 2026 at prices ranging from $971.16 to $971.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

7. The stock option vested in three equal annual installments, commencing one year after the date of grant.

	/s/ Christine A. Poon	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)